Mohammed Tanveer Hussain

Mr. Mohammed Tanveer Hussain


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2023 in Heliyon
Verified
Journal Article
Open access
MMM. Moniruzzaman
M. Moniruzzaman
MHMohammed Tanveer Hussain
Mohammed Tanveer Hussain
SASobur Ali
Sobur Ali
MHMonir Hossain
Monir Hossain
SHSakib Hossain
Sakib Hossain
ZMZahid Hayat Mahmud
Zahid Hayat Mahmud
Extended spectrum β-lactamase producing Escherichia coli (ESBL E. coli) is a primary concern for hospital and community healthcare settings, often linked to an increased incidence of nosocomial infections. This study investigated the characteristics of ESBL E. coli isolated from hospital environments and clinical samples. In total, 117 ESBL E. coli isolates were obtained. The isolates were subjected to molecular analysis for the presence of resistance and virulence genes, antibiotic susceptibility testing, quantitative adherence assay, ERIC-PCR for phylogenetic analysis and whole genome sequencing of four highly drug resistant isolates. Out of the 117 isolates, 68.4% were positive for blaCTX-M, 39.3% for blaTEM, 30.8% for blaNDM-1, 13.7% for blaOXA and 1.7% for blaSHV gene. Upon screening for diarrheagenic genes, no isolates were found to harbour any of the tested genes. In the case of extraintestinal pathogenic E. coli (ExPEC) virulence factors, 7.6%, 11%, 5.9%, 4.3% and 21.2% of isolates harbored the focG, kpsMII, sfaS, afa and iutA genes, respectively. At a temperature of 25°C, 14.5% of isolates exhibited strong biofilm formation with 21.4% and 28.2% exhibiting moderate and weak biofilm formation respectively, whereas 35.9% were non-biofilm formers. On the other hand at 37°C, 2.6% of isolates showed strong biofilm formation with 3.4% and 31.6% showing moderate and weak biofilm formation respectively, whereas, 62.4% were non-biofilm formers. Regarding antibiotic susceptibility testing, all isolates were found to be multidrug-resistant (MDR), with 30 isolates being highly drug resistant. ERIC-PCR resulted in 12 clusters, with cluster E−10 containing the maximum number of isolates. Hierarchical clustering and correlation analysis revealed associations between environmental and clinical isolates, indicating likely transmission and dissemination from the hospital environment to the patients. The whole genome sequencing of four highly drug resistant ExPEC isolates showed the presence of various antimicrobial resistance genes, virulence factors and mobile genetic elements, with isolates harbouring the plasmid incompatibility group IncF (FII, FIB, FIA). The sequenced isolates were identified as human pathogens with a 93.3% average score. This study suggests that ESBL producing E. coli are prevalent in the healthcare settings of Bangladesh, acting as a potential reservoir for AMR bacteria. This information may have a profound effect on treatment, and improvements in public healthcare policies are a necessity to combat the increased incidences of hospital-acquired infections in the country.

27 June 2024 in Viruses
Verified
Journal Article
Open access
PDF file
MHMohammed Tanveer Hussain
Mohammed Tanveer Hussain
Brent A. StanfieldBrent A. Stanfield
Brent A. Stanfield
DBDavid Bernstein
David Bernstein
Herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2) are two of the most prevalent human viruses worldwide. They are known to cause a variety of diseases including genital herpes, meningitis, encephalitis, cold sores and herpes stromal keratitis. The seropositive rate for HSV-1 is around 90%, whereas for HSV-2 it remains around 20–25% for the general adult population. The infections caused by these viruses remain difficult to study because a large proportion of infected individuals are asymptomatic. Furthermore, given the neurotropic characteristics of the virus, studies aimed at understanding the complex pathogenesis in humans is difficult. As a result, animal models have been developed to understand several characteristics of HSV biology, pathogenesis, disease and host responses to infection. These models are also commonly used as the first evaluation of new drugs and vaccines. There are several well-established animal models to study infection with HSV, including mice, guinea pigs and rabbits. Variables within the animal models depend on the species of animal, route of infection, viral strain, dosage, etc. This review aims at summarizing the most commonly used animal models to study HSV pathogenesis and therapies.

11 August 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
MHMohammed Tanveer Hussain
Mohammed Tanveer Hussain
KFKiran Fida
Kiran Fida
AAAmber A. Anderson
Amber A. Anderson
MRMd. Mostafijur Rahman
Md. Mostafijur Rahman
VCVladimir N. Chouljenko
Vladimir N. Chouljenko
Brent A. StanfieldBrent A. Stanfield
Brent A. Stanfield
Cervical cancer is a major cause of mortality worldwide and has been attributed to long-lasting (persistent) infections with the human papillomavirus (HPV). Although more than 50 types of HPVs are known the infect the genital tract, fewer than a dozen of them are regularly linked to cervical cancers leading to these types being designated as “high risk” HPVs. Worldwide, over 90% of cervical cancers arise from persistent high-risk human papillomavirus (HPV) infection and the infectious nature of the virus procures the need for preventative vaccines against cervical cancer. To address this, we have developed a live-attenuated herpes simplex virus type 1 (HSV-1) VC2-vectored vaccine expressing a catalytically inactive mutant of HPV-16 E7 (E7m) fused to the viral capsid protein VP26. Incorporation of E7m into the VC2 backbone resulted in stable incorporation of VP26-E7m fusion protein in cell free viral particles and detectable intracellular expression within infected cells. The recombinant virus (E7m VC-2) maintained growth kinetics comparable to parental VC2 in vitro, though plaque size was modestly reduced, suggesting a minimal fitness cost associated with transgene insertion. To evaluate prophylactic efficacy, mice received a one-dose vaccine schedule of E7m VC-2 prior to challenge with syngeneic HPV-16 E6/E7-expressing tumor cells. In mice that did develop tumors, growth kinetics were attenuated relative to unvaccinated animals. Importantly, neither E7m VC-2 nor adjuvanted E7m protein alone achieved statistically significant protection versus untreated controls. Immunohistochemical analysis of tumor tissue revealed markedly increased CD8+ T cell infiltration in E7m VC-2 vaccinated mice, demonstrating that vaccination promotes a cytotoxic immune microenvironment capable of restricting tumor progression. Three-dose vaccination of mice with E7m VC-2 induced a robust Th1-polarized immune response characterized by strong interferon-gamma (IFN-γ) secretion in response to HPV16 E7 expressing syngeneic cell lines, consistent with the induction of cell-mediated antitumor immunity and superior to responses elicited by adjuvanted E7m protein alone. With an extended three-dose vaccination schedule E7m VC-2 conferred significantly greater protection against tumor establishment relative to untreated controls (80% vs. 20% tumor-free). Collectively, these findings establish proof-of-concept for the HSV-1 VC2 platform as an effective vector for HPV-targeted cancer immunotherapy, delivering statistically significant prophylactic protection alongside potent induction of tumor-reactive CD8+ T cells. Future studies will incorporate both E6 and E7 antigens to broaden antigenic coverage, evaluate therapeutic efficacy in established tumor models, and optimize dosing regimens with the long-term goal of advancing this Louisiana-developed platform toward IND-enabling studies and clinical translation.